Treatment of lung cancer

Qualigen Therapeutics’ Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
Cancer, Acute myeloid leukemia, CEO, Company, Private Securities Litigation Reform Act, Pancreatic cancer, U.S. Securities and Exchange Commission, Annual report, Schwann, Nasdaq, IC50, 2021 Essex County Council election, AML, News, Nervous tissue, Form 10-K, Sarcoma, Abstract (summary), Therapy, Clinical trial, Society, Adult, RAS, Treatment of lung cancer, G4S, Orphan drug, FDA, IND, Patent, Partnership, Plexiform angiomyxoid myofibroblastic tumor, Prostate cancer, Program, University, ASCO, Risk, UofL, Protein, PDX, Fast Track, Growth, GLOBE, NMR, Security (finance), MPNST, Pharmaceutical industry, Aquaculture, Vaccine, Neurofibromatosis

CARLSBAD, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces that two abstracts featuring the Company’s RAS inhibitor program will be featured in the American Society for Clinical Oncology’s (ASCO) Annual Meeting Abstract Book, which was released online today.

Key Points: 
  • RAS-F binds all three main isoforms of RAS at low uM kd and modulates the RAS effector domain in NMR studies.
  • It suppresses RAS signaling pathways in transient assays and suppresses pancreatic tumor cell growth in soft agar with IC50s below 500nM.
  • RAS-F is a pre-clinical pan-RAS inhibitor that is active in vitro and in vivo against pancreatic cancer models.
  • RAS-F is a pre-clinical pan-RAS inhibitor that is active in vitro and in vivo against MPNST cancer models.

Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Friday, May 20, 2022
Cancer, Acute myeloid leukemia, Company, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Nasdaq, AML, News, RAS, Form 10-K, Therapy, Clinical trial, Fontainebleau Miami Beach, Adult, Treatment of lung cancer, G4S, Orphan drug, FDA, Patent, Industry, Conference, Prostate cancer, Risk, Protein, Fast Track, Security (finance), GLOBE, Pharmaceutical industry

CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics Management will present a corporate overview during the H.C. Wainwright Global Investment Conference.

Key Points: 
  • CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics Management will present a corporate overview during the H.C. Wainwright Global Investment Conference.
  • The conference is being held on May 23 26, 2022 at the Fontainebleau Hotel in Miami Beach, FL and virtually.
  • The presentation will provide an overview of the companys oncology drug pipeline and recent developments in its diagnostics business.
  • Viewable starting 7:00 AM ET, Tuesday, May 24, 2022
    Management will also be available for virtual one-on-one meetings.

ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

Retrieved on: 
Monday, May 23, 2022
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Severe acute respiratory syndrome coronavirus 2, Risk, Immunotherapy, Disease, Private Securities Litigation Reform Act, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Bladder cancer, GMP, Medicine, U.S. Securities and Exchange Commission, Biologics license application, Patient, Infection, Vaccine, NASDAQ, Cell death, Quality of life, Review, Interleukin, Clinical trial, CIS, Society, Cystectomy, COVID-19, Mortality, American Society of Clinical Oncology, Adult, BLA, Treatment of lung cancer, FDA, NK, Forward-looking statement, BCG, ASCO, NMIBC, Maintenance, Lung, Immune system, HIV, Valrubicin, SEC, Cancer, Pharmaceutical industry, ImmunityBio, Pembrolizumab

This immunotherapy represents a potential new option for bladder cancer patients who fail to respond to BCG, the current standard of care.

Key Points: 
  • This immunotherapy represents a potential new option for bladder cancer patients who fail to respond to BCG, the current standard of care.
  • Natural Killer (NK) and T cells are activated by BCG resulting in bladder cancer cell death.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.
  • ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.

Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Friday, May 13, 2022
Transfer, Cancer, Acute myeloid leukemia, G-quadruplex, CEO, Company, DNA, Private Securities Litigation Reform Act, Research, Disease, U.S. Securities and Exchange Commission, Annual report, Nasdaq, Technology transfer, AML, Patient, News, RAS, AACR, Form 10-K, Therapy, Infection, Clinical trial, AST, COVID-19, Adult, Marketing, University College London, Mortality, Treatment of lung cancer, G4S, Orphan drug, FDA, Patent, IND, Industry, Partnership, CRO, Prostate cancer, Program, Hospital, University, Risk, European Committee on Antimicrobial Susceptibility Testing, Protein, Pancreatic cancer, Fast Track, Growth, Security (finance), GLOBE, Pharmaceutical industry, Video game, Vaccine, Online gambling

We are on track with IND-enabling studies this year, and we are looking forward to discussing further progress in this development.

Key Points: 
  • We are on track with IND-enabling studies this year, and we are looking forward to discussing further progress in this development.
  • In March, we extended and expanded our research agreement with the University of Louisville Research Foundation to develop our RAS-F platform.
  • The end of the quarter also marked our return to fully managing the sales, marketing, and distribution of FastPack, which is our revenue producing diagnostic business.
  • As of April 1, 2022, we will be entitled to 100% of the revenue from FastPack sales that was previously shared with Sekisui.

Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, May 11, 2022
Acute myeloid leukemia, BTK, Research, FLT3, Webcast, University, BCL2, All rights reserved, Histology, Conference, HMA, Biliary tract, NF1, Annual report, Income, MCL1, MDS, KRAS, AML, News, Clinical trial, COVID-19, Microdeletion syndrome, Continuity, City, Leukemia, Biomarker, Cell cycle, Lymphatic system, GLOBE, Breast, Company, MD Anderson Cancer Center, Ara, BRAF, Cyclin E, CDK9, MAPK, Hematology, City of Hope, Program, PTPN11, Apoptosis, N, Venetoclax, Risk, R, CYCC, MYC, PLK1, EDT, Patient, NASDAQ, KIT, Lymphoma, Treatment of lung cancer, Safety, Drug development, Vaccine, Fine chemical, Pharmaceutical industry, Medical imaging, Online gambling, Airline, Broadcasting, CLL, Cyclacel, Hope

- Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate entering Phase 2 POC in 2H 2022 -

Key Points: 
  • - Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate entering Phase 2 POC in 2H 2022 -
    - Conference Call Scheduled for May 11, 2022 at 4:30 pm EDT -
    BERKELEY HEIGHTS, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced first quarter 2022 financial results and provided a business update.
  • Tax credit receipts of $3.6 million in respect of the financial year ended December 31, 2021, were received in May 2022.
  • Copyright 2022 Cyclacel Pharmaceuticals, Inc. All Rights Reserved.
  • The Cyclacel logo and Cyclacel are trademarks of Cyclacel Pharmaceuticals, Inc.

BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19

Retrieved on: 
Wednesday, May 4, 2022
COVID-19, Population, Mutation, Lung cancer, Phase, Treatment of lung cancer, Company, Safety, Research, ASA, Patient, Immunotherapy, FDA, Data, Urinary tract infection, Vaccine, AXL, Bemcentinib, Infection, STK11, Large-cell lung carcinoma, Pharmaceutical industry, NSCLC

BerGenBio has for many years pioneered research into AXL inhibition, with its lead development candidate bemcentinib showing clinical potential in oncology and infectious disease.

Key Points: 
  • BerGenBio has for many years pioneered research into AXL inhibition, with its lead development candidate bemcentinib showing clinical potential in oncology and infectious disease.
  • BerGenBio is targeting 1stLine STK11 mutated Non-Squamous NSCLC patients, an extremely large patient population with very limited response to the standard of care treatments.
  • STK11 is an important tumor suppressor gene reported to confer immunotherapy resistance in NSCLC and is present in up to 20% of NSCLC patients.
  • With a focused strategy and rightsized organization BerGenBio plans to unlock significant potential value related to the two indications selected and define the path to market.

BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19

Retrieved on: 
Wednesday, May 4, 2022
COVID-19, Population, Mutation, Lung cancer, Phase, Treatment of lung cancer, Company, Safety, Research, ASA, Patient, Immunotherapy, FDA, Data, Urinary tract infection, Vaccine, AXL, Bemcentinib, Infection, STK11, Large-cell lung carcinoma, Pharmaceutical industry, NSCLC

BerGenBio has for many years pioneered research into AXL inhibition, with its lead development candidate bemcentinib showing clinical potential in oncology and infectious disease.

Key Points: 
  • BerGenBio has for many years pioneered research into AXL inhibition, with its lead development candidate bemcentinib showing clinical potential in oncology and infectious disease.
  • BerGenBio is targeting 1stLine STK11 mutated Non-Squamous NSCLC patients, an extremely large patient population with very limited response to the standard of care treatments.
  • STK11 is an important tumor suppressor gene reported to confer immunotherapy resistance in NSCLC and is present in up to 20% of NSCLC patients.
  • With a focused strategy and rightsized organization BerGenBio plans to unlock significant potential value related to the two indications selected and define the path to market.

Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President

Retrieved on: 
Friday, April 29, 2022
Adult, Protein, Patent, U.S. Securities and Exchange Commission, Cancer, Treatment of lung cancer, Patient, Nasdaq, FDA, GLOBE, Leadership, Therapy, Private Securities Litigation Reform Act, Shishir, Growth, Risk, RAS, Clinical trial, Company, Senior, Orphan drug, Marketing, Security (finance), AML, News, Acute myeloid leukemia, Prostate cancer, Fast Track, Industry, G4S, Form 10-K, Pharmaceutical industry

With the return of the sales and marketing of FastPack last month, our diagnostics business is an essential asset to the strategic success of the Company.

Key Points: 
  • With the return of the sales and marketing of FastPack last month, our diagnostics business is an essential asset to the strategic success of the Company.
  • Therefore, it is only fitting that we now entrust Shishir with implementing our plans to grow and evolve our diagnostics business, commented Michael Poirier, Qualigens Chief Executive Officer and Chairman.
  • We are confident in Shishirs leadership to drive growth and technological development in this cornerstone of our business operations.
  • These statements include those related to the Company's prospects and strategy for the Companys diagnostics business and its development of therapeutic drug candidates.

ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Thursday, April 28, 2022
Biotechnology, Infectious Diseases, Health, Clinical Trials, Oncology, ASCO, U.S. Securities and Exchange Commission, Interleukin, Vaccine, GMP, Associate, Treatment of lung cancer, Patient, Infection, BCG, FDA, Annual general meeting, HIV, Private Securities Litigation Reform Act, COVID-19, American Society of Clinical Oncology, Food, Forward-looking statement, Disease, Clinical trial, CIS, 2021 Essex County Council election, DAMP, UCLA, IL15, NASDAQ, NMIBC, Society, SEC, Review, Immunotherapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, ImmunityBio, Urology

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today its abstracts were accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, in Chicago.

Key Points: 
  • ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today its abstracts were accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, in Chicago.
  • ImmunityBio is a clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases.
  • These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.

Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas

Retrieved on: 
Tuesday, April 19, 2022
News, Lymphoma, Cancer, Simon, Cytokinesis, DNA, MYC, PLK, MD Anderson Cancer Center, Biliary tract, COVID-19, CYCC, Lymphatic system, Oncology, NASDAQ, Research, Annual report, Half-life, Acceleration, Histology, GLOBE, Department, Patient, All rights reserved, Biomarker, Cell, Lung, Trial of the century, Hematology, Cell cycle, Company, Leukemia, Cyclacel, City, PLK1, Neoplasm, Safety, Cell division, Treatment of lung cancer, Risk, KRAS, Breast, Senior, Therapy, Mitosis, Survival, Pharmaceutical industry, Medical imaging

We also look forward to reporting initial data from the fadraciclib clinical study in advanced solid tumors during the first half of 2022.

Key Points: 
  • We also look forward to reporting initial data from the fadraciclib clinical study in advanced solid tumors during the first half of 2022.
  • In preclinical studies CYC140 has demonstrated promising activity in multiple solid tumors and leukemias.
  • In addition to patients with certain PLK1 over-expressing tumors, the study will enroll patients with MYC amplified and KRAS-mutated cancers in which PLK1 inhibition may be effective.
  • If successful, CYC140 may provide new treatment options for patients with advanced solid tumors or lymphomas.